Blocking [211At]astatide accumulation in normal tissues: Preliminary evaluation of seven potential compounds

Nuclear Medicine and Biology

Volumn 25, Issue 4, 1998, Pages 351-357

  Larsen, Roy H ^a   Slade, Susan ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Particles; Astatine 211; Normal tissue toxicity; Radiotherapy

Indexed keywords

ASTATINE 211; CYSTEINE; MONOVALENT CATION; PERIODATE SODIUM; POTASSIUM IODIDE; SODIUM IODIDE I 131; SODIUM PERCHLORATE; SUCCIMER; THIOCYANATE SODIUM; UNITHIOL; ANION; ASTATINE; RADIOACTIVE IODINE; THIOL DERIVATIVE;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSIMETRY; DRUG ACCUMULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LINEAR ENERGY TRANSFER; MOUSE; NONHUMAN; RADIOISOTOPE DISTRIBUTION; ANIMAL; BAGG ALBINO MOUSE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; LD 50; RADIATION INJURY; RADIOTHERAPY; TISSUE DISTRIBUTION;

ANIMALS; ANIONS; ASTATINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; INJECTIONS, INTRAPERITONEAL; IODINE RADIOISOTOPES; LETHAL DOSE 50; MICE; MICE, INBRED BALB C; RADIATION INJURIES, EXPERIMENTAL; RADIOTHERAPY; SULFHYDRYL COMPOUNDS; TISSUE DISTRIBUTION;

EID: 0031595425     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(97)00230-8     Document Type: Article

References (35)

1. Appelman E. H. The oxidation states of astatine in aqueous solution. J. Am. Chem. Soc. 83:1960;803-807.
2. Ashling C. W., Durbin P. W., Johnston M. J., Parrott M. W. Demonstration of the concentration of astatine-211 in the mammary tissue of the rat. Endocrinology. 64:1959;579-585.
3. 211At α-particle radiotherapy for undifferentiated thyroid cancer. Acta Radiol. (suppl.). 376:1991;174-175.
4. 211At). Radiochim. Acta. 47:1989;113-118.
5. Cobb L. M., Harrison A., Butler S. A. Toxicity of astatine-211 in the mouse. Human Toxicol. 7:1988;529-534.
6. 2 fragment. Cancer Res. 50:1990;3514-3520.
7. 211At]astato-N-piperidinoethylbenzamide. Nucl. Med. Biol. 22:1995;467-474.
8. Hall E. J. Radiobiology for the Radiologist. 3rd edn. 1988;161-177 Lippincott, Philadelphia.
9. Hamilton J. G., Durbin P. W., Parrott M. Accumulation of astatine-211 by thyroid gland in man. Med. Proc. Soc. Exp. Biol. 86:1954;366-369.
10. Hamilton J. G., Durbin P. W., Parrott M. The accumulation and destructive action of astatine-211 (eka-iodine) in the thyroid gland of rats and monkeys. J. Clin. Endocrinol. Metab. 14:1954;1161-1178.
11. Hamilton J. G., Durbin P. W., Ashling C. W. and Johnston M. E. (1956) Physiological and biochemical studies of astatine-211 (eka-iodine) In: Proceedings of the 10th Conference on the Peaceful Use of Atomic Energy, pp. 175-181, New York.
12. Jones S. B., Tiffany L. J., Garmestani K., Gansow O., Kozak R. W. Evaluation of dithiol chelating agents as potential adjuvants for anti-IL-2 receptor lead or bismuth alpha radioimmunotherapy. Nucl. Med. Biol. 23:1996;105-113.
13. Kugler H. K., Keller C. Gmelin Handbook of Inorganic Chemistry Astatine . 8th edn. 1985;Springer, Berlin.
14. 211At-TP-3 monoclonal antibody Comparison with astatine-211-labeled bovine serum, free astatine-211 and external-beam X rays . Radiat. Res. 139:1994;178-184.
15. 211At in a murine intraperitoneal tumor model. Gynecol. Oncol. 57:1995;9-15.
16. 211At reaction. Appl. Radiat. Isot. 47:1996;135-143.
17. Lewis R. J. Sax's Dangerous Properties of Industrial Materials. 9th edn. 1996;Van Nostrand Reinhold, New York.
18. 211At]Methylene blue for targeted radiotherapy of human melanoma xenografts Dose fractionation in the treatment of cutaneous tumors . Eur. J. Cancer. 32A:1996;1240-1247.
19. 211At-methylene blue for targeted radiotherapy of disseminated melanoma Microscopic analysis of tumour versus normal tissue damage . Eur. J. Cancer. 32A:1996;1986-1994.
20. Ludwig R., Fischer S., Dreyer R., Jacobi R., Beger J. Complex formation betwen astatine(I) and sulfur-containing chelating ligands. Polyhedron. 10:1991;11-17.
21. 1 and Balb/c (nu/nu) mice A long-term survival study with histologic analysis . Int. J. Radiat. Oncol. Biol. Phys. 35:1996;69-80.
22. Milesz S., Norseev Y. V., Szücs Z., Vasáros L. Characterization of DTPA complexes and conjugated antibodies of astatine. J. Radioanal. Nucl. Chem. Lett. 137:1989;365-372.
23. Milesz S., Norseev Y. V., Szücs Z., Vasáros L. Preparation of astatine-labeled monoclonal antibodies. Radiochemistry. 37:1995;233-237.
24. Schellabarger C. J., Durbin P. W., Parrott M. W., Hamilton J. G. Effects of thyroxine and KSCN on capacity of rat thyroid gland to accumulate astatine. Proc. Soc. Exp. Biol. Med. 87:1954;626-629.
25. Schellabarger C. J., Godwin J. T. Studies of the thyroidal uptake of astatine in the rat. J. Clin. Endocrinol. Metab. 14:1954;1149-1160.
26. Schumann D., Milesz S., Jovchev M., So B. C., Khalkin V. Nitrilotriacetate complex of univalent astatine. Radiochim. Acta. 56:1992;173-175.
27. 211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res. 54:1994;5414-5419.
28. 211At]astato-2′-deoxyuridine, an α-particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res. 56:1996;1204-1209.
29. Vedeneyev V. I., Gurvich L. V., Kondrat'yev V. N., Medvedev V. A., Frankevich Y. L. Bond Energies, Ionization Potentials, and Electron Affinities. 1966;St. Martin's Press, New York.
30. Visser G. W. M., Diemer E. L. Inorganic astatine chemistry Formation of complexes of astatine . Radiochim. Acta. 33:1983;145-151.
31. Visser G. M., Diemer E. L., Kaspersen F. M. The nature of the astatine-protein bond. Int. J. Appl. Radiat. Isot. 32:1981;905-912.
32. Visser G. M. Inorganic astatine chemistry Part II. The chameleon behavior and electrophilicity of At-species . Radiochim. Acta. 47:1989;97-103.
33. 2. Nucl. Med. Biol. 20:1993;917-927.
34. Windholz M. The Merck Index. 10th ed. 1983;Merck, Rahway, NJ.
35. Zalutsky M. R., McLendon R. E., Garg P. K., Archer G. E., Schuster J. M., Bigner D. D. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res. 54:1994;4719-4725.